ALRN-6924 vs Apratoxin A
Head-to-head comparison of ALRN-6924 (ALRN-6924 dual MDM2/MDMX stapled p53 mimetic peptide) and Apratoxin A (Apratoxin A) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | ALRN-6924 | Apratoxin A |
|---|---|---|
| Category | Experimental | Experimental |
| Full Name | ALRN-6924 dual MDM2/MDMX stapled p53 mimetic peptide | Apratoxin A |
| Molecular Weight | N/A | N/A |
| Half-Life | Hours to days depending on formulation | N/A |
| Amino Acids | N/A | N/A |
| Typical Dose | Varies by clinical protocol | N/A in humans; nanomolar in vitro |
| Route | Intravenous/Subcutaneous | Intraperitoneal / Intravenous (preclinical) |
| Purity | ≥98% | ≥98% |
| Studies Count | 40 | 140 |
| Research Status | Clinical | Pre-clinical |
ALRN-6924 Benefits
- ✓p53 reactivation
- ✓dual MDM2/MDMX inhibition
- ✓protease resistance
- ✓tumor cell apoptosis
Apratoxin A Benefits
- ✓antineoplastic
- ✓anti-angiogenic
- ✓Sec61 inhibition
- ✓anti-proliferative
ALRN-6924 Dosing
Clinical trial protocol dosing|Intermittent administration|Research-only escalation
Apratoxin A Dosing
preclinical in vitro nanomolar use|animal studies only|no human dosing established
ALRN-6924 Side Effects
- ⚠nausea
- ⚠fatigue
- ⚠myelosuppression
Apratoxin A Side Effects
- ⚠hepatotoxicity
- ⚠general cytotoxicity
- ⚠GI toxicity
Research Overview
ALRN-6924
ALRN-6924 is one of the best-known stapled peptide therapeutics and has advanced into human oncology studies. Literature shows that hydrocarbon stapling can improve target affinity, serum stability, and cellular activity for this p53-mimetic scaffold.
Apratoxin A
Apratoxin A is a well-studied lead compound for targeting secretory and membrane protein biogenesis in cancer cells. Medicinal chemistry programs around apratoxins focus on improving selectivity and reducing hepatotoxicity while preserving potency.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.